First-Line Pembrolizumab Plus Olaparib Maintenance Misses Survival End Points in Metastatic Nonsquamous NSCLC
Pembrolizumab plus olaparib as first-line maintenance therapy did not improve survival in patients with metastatic nonsquamous non–small cell lung cancer.